NEO - NeoGenomics launches RaDaR test to detect minimal residual disease

2023-03-16 07:49:47 ET

• NeoGenomics ( NASDAQ: NEO ) said its RaDaR liquid biopsy test for molecular/minimal residual disease (MRD) was now commercially available.
• MRD refers to the very small number of cancer cells which may remain in the body during or after treatment.
• The company added that the announcement comes after several publications showed the clinical utility of the test, mainly in the breast cancer space.
• The test is available to order for breast, colorectal, lung, and head and neck cancer, NeoGenomics noted.
• RaDaR was available over the last year for use in clinical research studies and pharmaceutical collaborations and has now become available to U.S. clinicians., according to the company.
• "The RaDaR assay addresses one of the most difficult challenges in oncology diagnostics by allowing oncologists to spot small amounts of cancer cells with greater sensitivity and much earlier than with standard tests," said NeoGenomics CEO Chris Smith.
• NEO +0.81% to 18.76 premarket March 16

For further details see: